Malignancy, a real risk in patients using anti-TNF drugs for Crohn’s disease?-Reference-Cited by-同舟云学术

Malignancy, a real risk in patients using anti-TNF drugs for Crohn’s disease?

Published:2024-08-29 Issue:2 Volume:10 Page:1-6
ISSN:
Container-title:Journal of Case Reports and Images in Pathology
language:en
Short-container-title:J Case Rep Images Pathol

Author:

Gabriela Díaz Karla¹,Rodriguez-Paredes Grecia Guadalupe¹,Lizardo-Thiebaud María José²,Prado-Aguirre Alessandra³,Burbano-Rodriguez Sara²,Martínez-Benitez Braulio⁴

Affiliation:

1. Medical student, School of Medicine, Universidad Popular del Estado de Tlaxcala, Tlaxcala, Mexico

2. Medical Resident, Department of Anatomical Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

3. Medical student, Faculty of Medicine, Universidad Autónoma de Coahuila, Unidad Torreón, Mexico

4. Adjunct Professor of Pathology, Department of Anatomical Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Abstract

Introduction: Crohn’s disease (CD) is a subtype of inflammatory bowel disease. Mucosal healing has become the main target in therapy and the most consequential treatment has been biologic agents, such as anti-TNF agents. The benefits of anti-TNF agents are associated with an increase in the risk of opportunistic infections and the development of malignancies. Case Report: A 58-year-old woman with the diagnosis of a stricturing, non-penetrating Crohn’s disease, underwent a surgical intervention for treatment of both Crohn’s disease and an ovarian tumor. The diagnosis was of two primary tumors, an ovarian and an endometrial carcinoma. Conclusion: The association between the use anti-TNF agents and tumors has been narrowed to specific tumors. There is no association between the development of genitourinary tumors and treatment with anti-TNF agents. However, current data has demonstrated synchronicity between IBD and endometriosis. The pro-inflammatory profile seen in IBD might enhance the occurrence and transformation of endometriotic foci. Their link to ovarian tumors seen in IBD patients remains an open question.

Publisher

Edorium Journals Pvt. Ltd.

Reference44 articles.

1. Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers 2020;6(1):22.

2. Cheifetz AS, Feuerstein JD. Treatment of Inflammatory Bowel Disease with Biologics. 1ed. Cheifetz A, Feuerstein J, editors. Vol. 1. Cham: Springer Nature. 2018. p. 1–160.

3. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012;119(3):651–65.

4. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: New pathways, new indications, and new drugs. Drug Discov Today 2009;14(23–24):1082–8.

5. Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56(6):489–526.